106 related articles for article (PubMed ID: 1606628)
1. Molecular design of potent inhibitor specific for cathepsin B based on the tertiary structure prediction.
Sumiya S; Yoneda T; Kitamura K; Murata M; Yokoo C; Tamai M; Yamamoto A; Inoue M; Ishida T
Chem Pharm Bull (Tokyo); 1992 Feb; 40(2):299-303. PubMed ID: 1606628
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for development of cathepsin B-specific noncovalent-type inhibitor: crystal structure of cathepsin B-E64c complex.
Yamamoto A; Tomoo K; Matsugi K; Hara T; In Y; Murata M; Kitamura K; Ishida T
Biochim Biophys Acta; 2002 Jun; 1597(2):244-51. PubMed ID: 12044902
[TBL] [Abstract][Full Text] [Related]
3. X-ray crystal structure of papain complexed with cathepsin B-specific covalent-type inhibitor: substrate specificity and inhibitory activity.
Matsumoto K; Murata M; Sumiya S; Mizoue K; Kitamura K; Ishida T
Biochim Biophys Acta; 1998 Mar; 1383(1):93-100. PubMed ID: 9546050
[TBL] [Abstract][Full Text] [Related]
4. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro.
Murata M; Miyashita S; Yokoo C; Tamai M; Hanada K; Hatayama K; Towatari T; Nikawa T; Katunuma N
FEBS Lett; 1991 Mar; 280(2):307-10. PubMed ID: 2013328
[TBL] [Abstract][Full Text] [Related]
5. pH Dependence of inhibitors targeting the occluding loop of cathepsin B.
Cathers BE; Barrett C; Palmer JT; Rydzewski RM
Bioorg Chem; 2002 Aug; 30(4):264-75. PubMed ID: 12392705
[TBL] [Abstract][Full Text] [Related]
6. Substrate specificity of bovine cathepsin B and its inhibition by CA074, based on crystal structure refinement of the complex.
Yamamoto A; Tomoo K; Hara T; Murata M; Kitamura K; Ishida T
J Biochem; 2000 Apr; 127(4):635-43. PubMed ID: 10739956
[TBL] [Abstract][Full Text] [Related]
7. Binding mode of CA074, a specific irreversible inhibitor, to bovine cathepsin B as determined by X-ray crystal analysis of the complex.
Yamamoto A; Hara T; Tomoo K; Ishida T; Fujii T; Hata Y; Murata M; Kitamura K
J Biochem; 1997 May; 121(5):974-7. PubMed ID: 9192742
[TBL] [Abstract][Full Text] [Related]
8. Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro.
Ohshita T; Nikawa T; Towatari T; Katunuma N
Eur J Biochem; 1992 Oct; 209(1):223-31. PubMed ID: 1382984
[TBL] [Abstract][Full Text] [Related]
9. Expression and alteration of the S2 subsite of the Leishmania major cathepsin B-like cysteine protease.
Chan VJ; Selzer PM; McKerrow JH; Sakanari JA
Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):113-7. PubMed ID: 10229665
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors.
Turk D; Podobnik M; Popovic T; Katunuma N; Bode W; Huber R; Turk V
Biochemistry; 1995 Apr; 34(14):4791-7. PubMed ID: 7718586
[TBL] [Abstract][Full Text] [Related]
11. The binding mode of an E-64 analog to the active site of cathepsin B.
Feng MH; Chan SL; Xiang Y; Huber CP; Lim C
Protein Eng; 1996 Nov; 9(11):977-86. PubMed ID: 8961350
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Structure-Activity Relationship Study of Epoxysuccinyl-Peptide Derivatives as Cathepsin B Inhibitors.
Zhang X; Yang X; Wang H; Li S; Guo K; Jiang D; Xiao J; Liang D
Biol Pharm Bull; 2017 Aug; 40(8):1240-1246. PubMed ID: 28502922
[TBL] [Abstract][Full Text] [Related]
13. Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.
LaLonde JM; Zhao B; Smith WW; Janson CA; DesJarlais RL; Tomaszek TA; Carr TJ; Thompson SK; Oh HJ; Yamashita DS; Veber DF; Abdel-Meguid SS
J Med Chem; 1998 Nov; 41(23):4567-76. PubMed ID: 9804696
[TBL] [Abstract][Full Text] [Related]
14. Epoxysuccinyl dipeptides as selective inhibitors of cathepsin B.
Gour-Salin BJ; Lachance P; Plouffe C; Storer AC; Ménard R
J Med Chem; 1993 Mar; 36(6):720-5. PubMed ID: 8459399
[TBL] [Abstract][Full Text] [Related]
15. Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.
Greenspan PD; Clark KL; Tommasi RA; Cowen SD; McQuire LW; Farley DL; van Duzer JH; Goldberg RL; Zhou H; Du Z; Fitt JJ; Coppa DE; Fang Z; Macchia W; Zhu L; Capparelli MP; Goldstein R; Wigg AM; Doughty JR; Bohacek RS; Knap AK
J Med Chem; 2001 Dec; 44(26):4524-34. PubMed ID: 11741472
[TBL] [Abstract][Full Text] [Related]
16. Crystallization and preliminary X-ray study of the cathepsin B complexed with CA074, a selective inhibitor.
Yamamoto A; Kaji T; Tomoo K; Ishida T; Inoue M; Murata M; Kitamura K
J Mol Biol; 1992 Oct; 227(3):942-4. PubMed ID: 1404397
[TBL] [Abstract][Full Text] [Related]
17. CA074 methyl ester: a proinhibitor for intracellular cathepsin B.
Buttle DJ; Murata M; Knight CG; Barrett AJ
Arch Biochem Biophys; 1992 Dec; 299(2):377-80. PubMed ID: 1444478
[TBL] [Abstract][Full Text] [Related]
18. Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor.
Tomoo K
Curr Top Med Chem; 2010; 10(7):696-707. PubMed ID: 20337581
[TBL] [Abstract][Full Text] [Related]
19. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity.
Musil D; Zucic D; Turk D; Engh RA; Mayr I; Huber R; Popovic T; Turk V; Towatari T; Katunuma N
EMBO J; 1991 Sep; 10(9):2321-30. PubMed ID: 1868826
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of NS-134 in complex with bovine cathepsin B: a two-headed epoxysuccinyl inhibitor extends along the entire active-site cleft.
Stern I; Schaschke N; Moroder L; Turk D
Biochem J; 2004 Jul; 381(Pt 2):511-7. PubMed ID: 15084146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
